Summary

Introduction to Europe Whole Genome and Exome Sequencing Market

The Europe whole genome and exome sequencing market is projected to reach $1,777.3 million by 2033 from $549.0 million in 2024, growing at a CAGR of 13.94% during the forecast period 2024-2033. Exome sequencing (WES) and whole genome sequencing (WGS) are cutting-edge genomic technologies that are revolutionising genetic analysis in Europe. WGS decodes the entire genome, including coding and non-coding regions, while WES only targets protein-coding exons, which contain the majority of disease-related variants. These techniques are boosting healthcare innovation by revolutionising clinical diagnostics, personalised medicine, and rare disease research. As technology continues to advance, costs come down, and their applications expand, WGS and WES are becoming indispensable tools in European genomics.

Market Introduction

The market for whole genome and exome sequencing in Europe is expanding significantly due to the growing demand for personalised medicine, growing adoption of clinical diagnostics, and improvements in genomic research. Exome sequencing (WES) concentrates on protein-coding regions, which are home to the majority of known disease-related variants, whereas whole genome sequencing (WGS) offers a thorough examination of a person's complete genetic composition. By facilitating early disease detection, precision treatment, and a better understanding of genetic disorders, these technologies are transforming the healthcare industry.

The need for WGS and WES has increased due to the rising incidence of cancer, neurological disorders, and rare diseases, especially in clinical and research settings. Market expansion is also being aided by government funding and initiatives for genomic medicine, as well as partnerships between biotech companies and healthcare organizations. Additionally, ongoing improvements in sequencing technology are reducing costs, making these advanced tools more accessible.

With stringent regulatory frameworks ensuring data accuracy and patient safety, Europe is at the forefront of genomic innovation. Expanding applications in oncology, infectious disease research, and reproductive health are also contributing to market growth. As genomic sequencing continues to evolve, it is set to play a crucial role in the future of precision medicine and biomedical research across Europe.

Market Segmentation

Segmentation 1: by End User
• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• Hospitals and Clinics
• Research and Academic Institutes
• Others

Segmentation 2: by Region
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Netherlands
o Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements and emerging applications in genome and exome sequencing, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors’ strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd
• Oxford Nanopore Technologies plc
• QIAGEN N.V.

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
1 Industry Outlook
1.1 Market Trends
1.1.1 Technological Innovations in the Sequencing Technology
1.1.2 Numerous Inorganic Growth Activities in the Market
1.2 COVID-19 Impact on Market
1.3 Regulatory Framework
1.3.1 Legal Requirements and Framework in Europe
1.4 Supply Chain Analysis
1.5 Market Dynamics Overview
1.5.1 Market Drivers
1.5.1.1 Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics
1.5.1.2 Rising Demand for Personalized Medicine Influencing the Demand for Whole Genome and Exome Sequencing
1.5.1.3 Lowering Costs and Increasing Accessibility of Genome Sequencing
1.5.1.4 Ongoing Whole Genome Sequencing Government Initiatives around the World
1.5.2 Market Restraints
1.5.2.1 Privacy and Ethical Concerns due to Increased Risk of Security Breaches
1.5.3 Market Opportunities
1.5.3.1 Increasing Usage of Sequencing Technology in Emerging Markets
2 Region
2.1 Regional Summary
2.2 Europe
2.2.1 Regional Overview
2.2.2 Driving Factors for Market Growth
2.2.3 Factors Challenging the Market
2.2.3.1 By End User
2.2.4 France
2.2.5 Germany
2.2.6 U.K.
2.2.7 Spain
2.2.8 Italy
2.2.9 Netherlands
2.2.10 Rest-of-Europe
3 Markets - Competitive Benchmarking & Company Profiles
3.1 Key Strategies and Development
3.2 Company Share Analysis
3.3 Company Profiles
3.3.1 Eurofins Scientific SE
3.3.1.1 Overview
3.3.1.2 Top Products
3.3.1.3 Top Competitors
3.3.1.4 Key Personnel
3.3.1.5 Analyst View
3.3.2 F. Hoffmann-La Roche Ltd
3.3.2.1 Overview
3.3.2.2 Top Products
3.3.2.3 Top Competitors
3.3.2.4 Key Personnel
3.3.2.5 Analyst View
3.3.3 Oxford Nanopore Technologies plc
3.3.3.1 Overview
3.3.3.2 Top Products
3.3.3.3 Top Competitors
3.3.3.4 Key Personnel
3.3.3.5 Analyst View
3.3.4 QIAGEN N.V.
3.3.4.1 Overview
3.3.4.2 Top Products
3.3.4.3 Top Competitors
3.3.4.4 Key Personnel
3.3.4.5 Analyst View
4 Research Methodology
4.1 Data Sources
4.1.1 Primary Data Sources
4.1.2 Secondary Data Sources
4.1.3 Data Triangulation
4.2 Market Estimation and Forecast
List of Figures
Figure 1: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023, 2026, and 2033
Figure 2: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023, 2026, and 2033
Figure 3: Key Events to Keep Track of within the Whole Genome and Exome Sequencing Market
Figure 4: Value and Supply Chain Analysis, Whole Genome and Exome Sequencing Market
Figure 5: Analysis of Market Navigating Factors, 2023-2033
Figure 6: Key Clinical Applications of Whole Genome and Whole Exome Sequencing
Figure 7: Number of Research Papers Mentioning Personalized Medicine in PubMed, 2010-2023
Figure 8: Decreasing Genome Sequencing Costs
Figure 9: Map of a Few Recent and Ongoing Government-Funded National Genomic-Medicine Initiatives
Figure 10: Examples of Security Breaches in Whole Genome and Exome Sequencing
Figure 11: France Whole Genome and Exome Sequencing Market, $Million, 2023-2033
Figure 12: Germany Whole Genome and Exome Sequencing Market, $Million, 2023-2033
Figure 13: U.K. Whole Genome and Exome Sequencing Market, $Million, 2023-2033
Figure 14: Spain Whole Genome and Exome Sequencing Market, $Million, 2023-2033
Figure 15: Italy Whole Genome and Exome Sequencing Market, $Million, 2023-2033
Figure 16: Netherlands Whole Genome and Exome Sequencing Market, $Million, 2023-2033
Figure 17: Rest-of-Europe Whole Genome and Exome Sequencing Market, $Million, 2023-2033
Figure 18: Strategic Initiatives, January 2021-April 2024
Figure 19: Share of Strategic Initiatives, January 2021-April 2024
Figure 20: Whole Genome and Exome Sequencing Market, Company Revenue Share Analysis, 2023
Figure 21: Data Triangulation
Figure 22: Top-Down and Bottom-Up Approach
Figure 23: Assumptions and Limitations
List of Tables
Table 1: Market Snapshot
Table 2: Opportunities across Regions
Table 3: Recent Technological Innovations
Table 4: Few Major Inorganic Growth Activities in the Whole Genome and Exome Sequencing Market
Table 5: Whole Genome and Exome Sequencing Market (by Region), $Million, 2023-2033
Table 6: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2023-2033

Press Release